198 related articles for article (PubMed ID: 15709992)
1. Metronidazole and risk of acute pancreatitis: a population-based case-control study.
Nørgaard M; Ratanajamit C; Jacobsen J; Skriver MV; Pedersen L; Sørensen HT
Aliment Pharmacol Ther; 2005 Feb; 21(4):415-20. PubMed ID: 15709992
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
[TBL] [Abstract][Full Text] [Related]
3. Risk of hospitalization for acute pancreatitis associated with conventional and atypical antipsychotics: a population-based case-control study.
Gasse C; Jacobsen J; Pedersen L; Mortensen PB; Nørgaard M; Sørensen HT; Johnsen SP
Pharmacotherapy; 2008 Jan; 28(1):27-34. PubMed ID: 18154471
[TBL] [Abstract][Full Text] [Related]
4. Statins and the risk of acute pancreatitis: a population-based case-control study.
Thisted H; Jacobsen J; Munk EM; Nørgaard B; Friis S; McLaughlin JK; Sørensen HT; Johnsen SP
Aliment Pharmacol Ther; 2006 Jan; 23(1):185-90. PubMed ID: 16393296
[TBL] [Abstract][Full Text] [Related]
5. Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a population-based case-control study.
Tetsche MS; Jacobsen J; Nørgaard M; Baron JA; Sørensen HT
Am J Gastroenterol; 2007 Feb; 102(2):275-8. PubMed ID: 17311649
[TBL] [Abstract][Full Text] [Related]
6. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study.
Floyd A; Pedersen L; Nielsen GL; Thorlacius-Ussing O; Sorensen HT
Am J Gastroenterol; 2003 Jun; 98(6):1305-8. PubMed ID: 12818274
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
Gessner BD; Bruce MG; Parkinson AJ; Gold BD; Muth PT; Dunaway E; Baggett HC
Clin Infect Dis; 2005 Nov; 41(9):1261-8. PubMed ID: 16206100
[TBL] [Abstract][Full Text] [Related]
8. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan.
Fukuda S; Shimoyama T; Tanaka M; Nakasato F; Fukushi M; Munakata A
Jpn J Infect Dis; 2006 Dec; 59(6):367-9. PubMed ID: 17186954
[TBL] [Abstract][Full Text] [Related]
9. Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis--results from a Swedish Case-Control Study.
Sundström A; Blomgren K; Alfredsson L; Wiholm BE
Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):141-9. PubMed ID: 16200654
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
Matsuhisa T; Kawai T; Masaoka T; Suzuki H; Ito M; Kawamura Y; Tokunaga K; Suzuki M; Mine T; Takahashi S; Sakaki N
Helicobacter; 2006 Jun; 11(3):152-8. PubMed ID: 16684262
[TBL] [Abstract][Full Text] [Related]
11. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis.
Sørensen HT; Jacobsen J; Nørgaard M; Pedersen L; Johnsen SP; Baron JA
Aliment Pharmacol Ther; 2006 Jul; 24(1):111-6. PubMed ID: 16803609
[TBL] [Abstract][Full Text] [Related]
12. One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection.
Hsu CC; Chen JJ; Hu TH; Lu SN; Changchien CS
Hepatogastroenterology; 2005; 52(65):1617-21. PubMed ID: 16201128
[TBL] [Abstract][Full Text] [Related]
13. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection.
Matsushima M; Suzuki T; Kurumada T; Watanabe S; Watanabe K; Kobayashi K; Deguchi R; Masui A; Takagi A; Shirai T; Muraoka H; Kobayashi I; Mine T
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):232-6. PubMed ID: 16460479
[TBL] [Abstract][Full Text] [Related]
14. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
15. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
[TBL] [Abstract][Full Text] [Related]
18. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study.
Paoluzi P; Iacopini F; Crispino P; Nardi F; Bella A; Rivera M; Rossi P; Gurnari M; Caracciolo F; Zippi M; Pica R
Helicobacter; 2006 Dec; 11(6):562-8. PubMed ID: 17083378
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children: a randomized, double-blind clinical trial.
Nguyen TV; Bengtsson C; Nguyen GK; Hoang TT; Phung DC; Sörberg M; Granström M
Helicobacter; 2008 Dec; 13(6):550-6. PubMed ID: 19166421
[TBL] [Abstract][Full Text] [Related]
20. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
